CT-388
Aliases: CT388 · dual GIP/GLP-1 agonist
CT-388 is a linear peptide targeting GLP-1R, GIPR, developed by Roche for undisclosed indications. As of Aug 15, 2024, its highest verified stage is Phase 1.
Phase 1· verified Aug 15, 2024
Identity
- Generic name
- —
- Brand names
- —
- Development codes
- CT-388
- Sponsor / originator
- Roche
- Route / formulation
- Subcutaneous injection
Development timeline
Trials
View all →| Registry ID | Phase | Status | Enrollment | Completion |
|---|---|---|---|---|
| Roche-CT388-Ph1 | Phase 1 | Recruiting | 80 | Mar 1, 2025 |